OSU as a Network Lead Academic Participating Site for the NCI NCTN

OSU 作为 NCI NCTN 网络主导学术参与网站

• 批准号: 9902398
• 负责人: DAVID P. CARBONE
• 金额: $ 109.99万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2019
• 资助国家: 美国
• 起止时间: 2019-03-28 至 2025-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9902398
• 关键词: Address; Adult; Advisory Committees; Affect; Area; Award; Basic Science; Biochemistry; Biological Markers; Biomedical Research; Biometry; Biotechnology; CEBPA gene; Cancer Biology; Cancer Center; Cancer Hospital; Cancer Patient; Center for Translational Science Activities; Clinic; Clinical; Clinical Data; Clinical Investigator; Clinical Oncology Supplement (K12); Clinical Research; Clinical Sciences; Clinical Trials; Clinical Trials Network; Comprehensive Cancer Center; Contracts; Data; Databases; Decitabine; Discipline; Disease; Education; Educational process of instructing; Educational workshop; Enrollment; Environment; Epidemiologist; FLT3 gene; Faculty; Fostering; Funding; Generations; Goals; Grant; Growth; Gynecologic Oncology; Health Personnel; Hematologic Neoplasms; Hematology; Hematopoietic Neoplasms; Image; Immunologics; Immunology; Infrastructure; Inpatients; Institutes; Investigational Therapies; Knowledge; Laboratory Scientists; Lead; Leadership; Learning; Malignant Neoplasms; Medical; Medical Oncology; Mentors; Minority; Modeling; Molecular Genetics; NCI Center for Cancer Research; National Clinical Trials Network; Nurses; Oblimersen; Ohio; Operative Surgical Procedures; Outcome; Outpatients; Pathologist; Patient-Focused Outcomes; Patients; Peer Review; Pentostatin; Performance; Pharmacists; Pharmacology; Phase; Physicians; Postdoctoral Fellow; Protocols documentation; Psychiatrist; Quality of life; Radiation Oncologist; Radiation Oncology; Radiation therapy; Research; Research Activity; Research Design; Research Institute; Research Personnel; Resources; Risk; Science; Scientist; Site; Solid Neoplasm; Structure; Support Groups; Surgical Oncologist; Surgical Oncology; Symptoms; Therapeutic; Therapeutic Agents; Time; Tissues; Toxic effect; Training; Translating; Translational trial; Tumor Biology; Universities; base; cancer clinical trial; cancer prevention; cancer therapy; career; career development; college; confirmatory trial; data submission; design; doctoral student; drug development; experience; high standard; improved; improved outcome; innovation; investigator-initiated trial; lenalidomide; leukemia; meetings; multidisciplinary; multimodality; next generation; novel; novel therapeutics; operation; patient population; pre-clinical; pre-doctoral; preclinical study; programs; recruit; research study; rituximab; success; targeted treatment; translational scientist; treatment trial; tumor heterogeneity; volunteer

PROJECT SUMMARY The goal of this application is to provide the infrastructure to support The Ohio State University's (OSU) participation in the scientific and clinical research activities of the NCI's NCTN Program as a Network Lead Academic Participating Site (OSU-LAPS). Faculty from OSU are integrated into the scientific and administrative activities, participate in meetings, manage multiple core labs, design studies and enroll patients in all existing adult NCTN network groups using OSU Comprehensive Cancer Center (OSUCCC) resources to leverage group resources. OSUCCC investigators develop and lead studies designed to enroll patients on multi-disciplinary treatment trials as well as develop and perform correlative science related research studies, bringing special expertise in hematologic malignancies and solid tumors. Our medical, hematologic, surgical and radiation oncologists, transplanters, psychiatrists, pathologists, cytogeneticists, translational and basic laboratory scientists, statisticians, epidemiologists, nurses, pharmacists, and clinical research coordinators help to frame the clinical and basic science questions whose answers contribute to improved patient outcomes and to understanding tumor biology. OSU-LAPS will offer innovative NCI trials to the OSU patient population, support scientific discoveries about tumor biology, find better treatments, and augment the quality of life for patients thus improving outcomes across the spectrum of cancers affecting adults. This comprehensive program aims to: 1) investigate new therapeutic agents, and their toxicities in Phase I to III NCI clinical trials; 2) evaluate the efficacy and toxicity of novel combinations based on preclinical data to exploit synergistic combinations more effectively; 3) develop multi-modal approaches using surgical, immunological, and radiotherapeutic therapies in optimal combinations; 4) integrate experts in molecular genetics, biochemistry, pharmacology, immunology, and biostatistics in the design and execution of therapeutic protocols; 5) improve cancer outcomes through discovery and education of pre and post-doctoral students, nurses, allied medical personnel and physicians, 6) understand and exploit tumor heterogeneity to fully exploit the value of targeted therapies, 7) improve the management of cancer related symptoms, 8) form the next generation of clinical investigators by offering them formal teaching and mentoring within the NCTN, and 9) enroll volunteering patients on trials.

项目概要 此应用程序的目标是提供基础设施来支持俄亥俄州立大学 (OSU) 作为网络负责人参与 NCI NCTN 计划的科学和临床研究活动 学术参与网站 (OSU-LAPS)。俄勒冈州立大学的教师被纳入科学和行政部门 活动、参加会议、管理多个核心实验室、设计研究并将患者纳入所有现有实验室 成人 NCTN 网络团体利用 OSU 综合癌症中心 (OSUCCC) 资源来利用团体 资源。 OSUCCC 研究人员开发并领导旨在招募多学科患者的研究 治疗试验以及开发和进行相关的科学相关研究，带来特殊的 血液系统恶性肿瘤和实体瘤方面的专业知识。我们的医疗、血液学、外科和放射学 肿瘤学家、移植师、精神科医生、病理学家、细胞遗传学家、转化和基础实验室 科学家、统计学家、流行病学家、护士、药剂师和临床研究协调员帮助制定框架 临床和基础科学问题，其答案有助于改善患者的治疗结果并 了解肿瘤生物学。 OSU-LAPS 将为 OSU 患者群体提供创新的 NCI 试验，支持 有关肿瘤生物学的科学发现，找到更好的治疗方法，并提高患者的生活质量 改善影响成人的各种癌症的结果。该综合计划旨在：1) 在 I 期至 III 期 NCI 临床试验中研究新的治疗药物及其毒性； 2）评估疗效 基于临床前数据的新型组合的毒性和毒性，以更有效地开发协同组合； 3）开发最佳的手术、免疫和放射治疗的多模式方法 组合； 4）整合分子遗传学、生物化学、药理学、免疫学等领域的专家 治疗方案设计和执行中的生物统计学； 5）通过发现改善癌症结果 博士前和博士后学生、护士、专职医务人员和医生的教育，6) 了解 并利用肿瘤异质性充分发挥靶向治疗的价值，7）改善肿瘤的管理 癌症相关症状，8）通过为下一代临床研究人员提供正规教学来培养他们 NCTN 内的指导，以及 9) 招募自愿患者参加试验。